Foundation Surgical Hospital of San Antonio has announced it has brought MAKOplasty®, a minimally iorthopedic knee procedure, to San Antonio. Foundation Surgical Hospital is the only hospital in San Antonio — and the second of only three hospitals in Texas — providing MAKOplasty partial knee resurfacing, an innovative and minimally invasive surgical solution that enables orthopedic surgeons to treat patients with early to mid-stage osteoarthritis of the knee before it has impacted their entire knee.

For the full story, Click Here

AstraZeneca and Pozen have submitted a marketing authorization application or MAA in the EU via the decentralized procedure for Vimovo tablets, a product under investigation for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing non-steroidal anti-inflammatory drug-associated ulcers. Vimovo is a fixed-dose combination of enteric coated naproxen and immediate release esomeprazole under co-development by AstraZeneca and Pozen.

For  the full story, Click Here

Research has shown a clear connection between depression and a loss of bone mass, leading to osteoporosis and fractures. Researchers of the Hebrew University of Jerusalem found that a link between depression and bone loss is particularly strong among young women. Osteoporosis is the most widespread degenerative disease in the developed world. Sufferers experience decrease in bone density, which often leads to bone fractures. In many cases, these fractures cause severe disability and even death.

For the full story, Click Here

In a study of more than 200 women ages 46 to 65, published in the American Journal of Clinical Nutrition, researchers found that the soy supplement did not appear to ward off bone-density loss over 3 years. In general, women on the supplement showed the same degree of bone loss as those given a placebo — though there was some evidence that a higher dose helped protect bone density in the hip.

Ellipse Technologies, Inc. has announced that it has received CE Mark for its MAGECTM Technology for the treatment of spinal deformity. The first application for this technology is for the treatment of spinal scoliosis in young children and teenagers. The CE Mark allows the Company to market the MAGEC System in the European Union and other countries that recognize the CE Mark for commercial distribution purposes.